Please use this identifier to cite or link to this item:
https://hdl.handle.net/10316/109149
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bezu, Lucillia | - |
dc.contributor.author | Silva, Lígia C. Gomes da | - |
dc.contributor.author | Dewitte, Heleen | - |
dc.contributor.author | Breckpot, Karine | - |
dc.contributor.author | Fucikova, Jitka | - |
dc.contributor.author | Spisek, Radek | - |
dc.contributor.author | Galluzzi, Lorenzo | - |
dc.contributor.author | Kepp, Oliver | - |
dc.contributor.author | Kroemer, Guido | - |
dc.date.accessioned | 2023-09-29T08:14:38Z | - |
dc.date.available | 2023-09-29T08:14:38Z | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 1664-3224 | pt |
dc.identifier.uri | https://hdl.handle.net/10316/109149 | - |
dc.description.abstract | The term "immunogenic cell death" (ICD) is commonly employed to indicate a peculiar instance of regulated cell death (RCD) that engages the adaptive arm of the immune system. The inoculation of cancer cells undergoing ICD into immunocompetent animals elicits a specific immune response associated with the establishment of immunological memory. Only a few agents are intrinsically endowed with the ability to trigger ICD. These include a few chemotherapeutics that are routinely employed in the clinic, like doxorubicin, mitoxantrone, oxaliplatin, and cyclophosphamide, as well as some agents that have not yet been approved for use in humans. Accumulating clinical data indicate that the activation of adaptive immune responses against dying cancer cells is associated with improved disease outcome in patients affected by various neoplasms. Thus, novel therapeutic regimens that trigger ICD are urgently awaited. Here, we discuss current combinatorial approaches to convert otherwise non-immunogenic instances of RCD into bona fide ICD. | pt |
dc.description.sponsorship | GK issupportedbytheLiguecontreleCancer(équipelabelisée); AgenceNationaldelaRecherche(ANR);Associationpour larecherchesurlecancer(ARC);CancéropôleIle-de-France; InstitutNationalduCancer(INCa);FondationBettencourt- Schueller;FondationdeFrance;FondationpourlaRecherche Médicale(FRM);theEuropeanCommission(ArtForce);the EuropeanResearchCouncil(ERC);theLabExImmuno- Oncology;theSIRICStratifiedOncologyCellDNARepair andTumorImmuneElimination(SOCRATE);theSIRIC CancerResearchandPersonalizedMedicine(CARPEM); andtheParisAllianceofCancerResearchInstitutes (PACRI). | pt |
dc.language.iso | eng | pt |
dc.publisher | Frontiers Media S.A. | pt |
dc.rights | openAccess | pt |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | pt |
dc.subject | ATP | pt |
dc.subject | autophagy | pt |
dc.subject | calreticulin | pt |
dc.subject | endoplasmic reticulum stress | pt |
dc.subject | HMGB1 | pt |
dc.subject | type I interferon | pt |
dc.title | Combinatorial strategies for the induction of immunogenic cell death | pt |
dc.type | article | - |
degois.publication.firstPage | 187 | pt |
degois.publication.issue | APR | pt |
degois.publication.title | Frontiers in Immunology | pt |
dc.peerreviewed | yes | pt |
dc.identifier.doi | 10.3389/fimmu.2015.00187 | pt |
degois.publication.volume | 6 | pt |
dc.date.embargo | 2015-01-01 | * |
uc.date.periodoEmbargo | 0 | pt |
item.openairetype | article | - |
item.fulltext | Com Texto completo | - |
item.languageiso639-1 | en | - |
item.grantfulltext | open | - |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
crisitem.author.researchunit | CQC - Coimbra Chemistry Centre | - |
crisitem.author.parentresearchunit | Faculty of Sciences and Technology | - |
crisitem.author.orcid | 0000-0003-0624-8819 | - |
Appears in Collections: | FCTUC Química - Artigos em Revistas Internacionais |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Combinatorial strategies for the induction of immunogenic cell death.pdf | 3.24 MB | Adobe PDF | View/Open |
Page view(s)
53
checked on Jul 17, 2024
Download(s)
45
checked on Jul 17, 2024
Google ScholarTM
Check
Altmetric
Altmetric
This item is licensed under a Creative Commons License